Vanguard Group Inc. Trims Stock Position in Illumina, Inc. $ILMN

Vanguard Group Inc. lessened its position in shares of Illumina, Inc. (NASDAQ:ILMN) by 1.9% during the 4th quarter, Holdings Channel reports. The institutional investor owned 14,355,380 shares of the life sciences company’s stock after selling 272,500 shares during the quarter. Vanguard Group Inc. owned about 0.09% of Illumina worth $1,882,852,000 at the end of the most recent quarter.

Several other institutional investors have also recently made changes to their positions in ILMN. MassMutual Private Wealth & Trust FSB lifted its position in Illumina by 7.9% in the fourth quarter. MassMutual Private Wealth & Trust FSB now owns 1,081 shares of the life sciences company’s stock valued at $142,000 after acquiring an additional 79 shares during the last quarter. Assetmark Inc. lifted its position in Illumina by 10.2% in the third quarter. Assetmark Inc. now owns 1,039 shares of the life sciences company’s stock valued at $99,000 after acquiring an additional 96 shares during the last quarter. Venturi Wealth Management LLC lifted its position in Illumina by 4.2% in the fourth quarter. Venturi Wealth Management LLC now owns 2,465 shares of the life sciences company’s stock valued at $323,000 after acquiring an additional 99 shares during the last quarter. Versant Capital Management Inc lifted its position in Illumina by 8.9% in the third quarter. Versant Capital Management Inc now owns 1,364 shares of the life sciences company’s stock valued at $130,000 after acquiring an additional 111 shares during the last quarter. Finally, Creative Capital Management Investments LLC lifted its position in Illumina by 160.0% in the fourth quarter. Creative Capital Management Investments LLC now owns 195 shares of the life sciences company’s stock valued at $26,000 after acquiring an additional 120 shares during the last quarter. Hedge funds and other institutional investors own 89.42% of the company’s stock.

Insider Activity

In other news, SVP Patricia Leckman sold 2,370 shares of the business’s stock in a transaction dated Wednesday, February 18th. The shares were sold at an average price of $116.18, for a total transaction of $275,346.60. Following the transaction, the senior vice president directly owned 16,321 shares in the company, valued at $1,896,173.78. The trade was a 12.68% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. 2.90% of the stock is currently owned by company insiders.

Illumina Price Performance

Shares of NASDAQ:ILMN opened at $120.37 on Thursday. The company has a 50-day simple moving average of $125.55 and a 200-day simple moving average of $126.43. Illumina, Inc. has a one year low of $73.86 and a one year high of $155.53. The company has a debt-to-equity ratio of 0.55, a quick ratio of 1.72 and a current ratio of 2.08. The stock has a market capitalization of $18.29 billion, a price-to-earnings ratio of 22.09, a PEG ratio of 2.46 and a beta of 1.49.

Illumina (NASDAQ:ILMN) last announced its earnings results on Thursday, February 5th. The life sciences company reported $1.35 EPS for the quarter, beating analysts’ consensus estimates of $1.26 by $0.09. Illumina had a net margin of 19.57% and a return on equity of 31.04%. The business had revenue of $1.16 billion during the quarter, compared to analysts’ expectations of $1.10 billion. During the same period in the prior year, the company earned $0.95 earnings per share. The business’s revenue was up 5.0% compared to the same quarter last year. Illumina has set its FY 2026 guidance at 5.050-5.200 EPS. On average, analysts predict that Illumina, Inc. will post 5.12 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently weighed in on the stock. Canaccord Genuity Group boosted their price target on shares of Illumina from $130.00 to $150.00 and gave the company a “hold” rating in a research report on Monday, January 26th. Guggenheim boosted their price target on shares of Illumina from $144.00 to $170.00 and gave the company a “buy” rating in a research report on Monday, January 26th. JPMorgan Chase & Co. reduced their price target on shares of Illumina from $130.00 to $120.00 and set a “neutral” rating for the company in a research report on Friday, February 6th. Wall Street Zen raised shares of Illumina from a “buy” rating to a “strong-buy” rating in a report on Saturday, February 14th. Finally, Evercore set a $150.00 target price on shares of Illumina in a report on Friday, February 6th. Six equities research analysts have rated the stock with a Buy rating, ten have assigned a Hold rating and two have given a Sell rating to the company’s stock. According to data from MarketBeat.com, the company currently has an average rating of “Hold” and a consensus target price of $129.69.

Illumina Profile

Illumina, Inc (NASDAQ: ILMN) is a global life sciences company that develops, manufactures and markets integrated systems for the analysis of genetic variation and function. Headquartered in San Diego, California and founded in 1998, Illumina offers a range of sequencing and array-based technologies used by academic researchers, clinical laboratories, pharmaceutical and biotechnology companies, consumer genomics firms and agricultural researchers to enable discovery, translational research and clinical applications.

The company’s product portfolio includes next-generation sequencing (NGS) platforms and associated consumables, microarrays for genotyping and methylation analysis, library preparation kits and targeted assays.